Where are we in 2021 with heart failure with reduced ejection fraction?-current outlook and expectations from new promising clinical trials.

Authors:
Dębska-Kozłowska A; Książczyk M; Lelonek M.

Journal:
Heart Fail Rev

Publication Year: 2021

DOI:
10.1007/s10741-021-10120-x

PMCID:
PMC8898246

PMID:
34050489

View on PubMed View on PMC View Publisher
Journal Information

Full Title: Heart Fail Rev

Abbreviation: Heart Fail Rev

Country: Unknown

Publisher: Unknown

Language: N/A

Publication Details

Subject Category: Cardiology

Available in Europe PMC: Yes

Available in PMC: Yes

PDF Available: No

Related Papers from Same Journal
ACEI/ARB and beta-blocker therapies for preventing cardiotoxicity of antineoplastic agents in breas…
Gao Y; Wang R; Jiang J and 3 more (2023) - Transparency Score: 3/6
Acute advanced aortic stenosis.
Avvedimento M; Angellotti D; Ilardi F and 11 more (2023) - Transparency Score: 3/6
Advance of echocardiography in cardiac amyloidosis.
Liang S; Liu Z; Li Q and 2 more (2023) - Transparency Score: 2/6
Artificial intelligence models in prediction of response to cardiac resynchronization therapy: a sy…
Nazar W; Szymanowicz S; Nazar K and 4 more (2023) - Transparency Score: 3/6
Effectiveness of mobile telemonitoring applications in heart failure patients: systematic review of…
Rebolledo Del Toro M; Herrera Leaño NM; Barahona-Correa JE and 3 more (2023) - Transparency Score: 4/6
View All Papers from This Journal
Transparency Score
1/6
0.0% Transparent
Transparency Indicators
Click on green indicators to view evidence text
Core Indicators
Data Sharing
Code Sharing
Evidence found in paper:

"Declarations Conflict of interestMałgorzata Lelonek participated in clinical trials on molecules empagliflozin, sacubitril/valsartan, omecamtiv mecarbil, consultation and lecture honoraria from AstraZeneca, Novartis, Bayer, Amgen, Boehringer Ingelheim. Agnieszka Dębska-Kozłowska and Marcin Książczyk have no conflict of interest to declare. Conflict of interest Małgorzata Lelonek participated in clinical trials on molecules empagliflozin, sacubitril/valsartan, omecamtiv mecarbil, consultation and lecture honoraria from AstraZeneca, Novartis, Bayer, Amgen, Boehringer Ingelheim. Agnieszka Dębska-Kozłowska and Marcin Książczyk have no conflict of interest to declare."

Funding Disclosure
Protocol Registration
Open Access
Additional Indicators
Replication
Novelty Statement
Assessment Info

Tool: rtransparent

OST Version: N/A

Last Updated: Aug 05, 2025